THERAPY DOSSIER · th-964147f45716

NF-kappaB inhibitor (pharmacologic inhibition), with genetic TLR4 deficiency as comparator strategy

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT05031351 ↗PHASE2unknown

Nuclear factor kappa beta inhibition in patients with amyotrophic lateral sclerosis: phase II randomized placebo controlled trial (Withania somnifera)

ALS

Enrolment: 75 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29925937 ↗2018Reported benefit

Attenuation of ventilation-induced diaphragm dysfunction through toll-like receptor 4 and nuclear factor-kappaB in a murine endotoxemia model.

MouseEndotoxin/LPSC57BL/6 (wild-type) and TLR4-deficientMale

Model: Mechanical ventilation (6 mL/kg or 10 mL/kg tidal volume) for 8 h with or without endotoxaemia, causing ventilator-induced diaphragm dysfunction

Mechanical ventilation with endotoxaemia aggravated diaphragmatic injury, proteolysis, oxidative loading, autophagy and apoptosis and reduced muscle fibre size. This endotoxin-exacerbated ventilator-induced diaphragm dysfunction was attenuated by pharmacologic NF-kappaB inhibition or by TLR4 defici…

Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…